secwatch.observer — SEC 8-K summary
======================================

Issuer:     EyePoint, Inc. (EYPT)
CIK:        0001314102
Form:       8-K
Filed at:   2026-03-04T23:59:59+00:00
Accession:  0001193125-26-089856
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

EyePoint Q4 net loss $67.6M; DURAVYU wet AMD Phase 3 topline due mid-2026
-------------------------------------------------------------------------

- Net loss Q4 $67.6M ($0.81/sh) vs $41.4M ($0.64); FY net loss $232M ($3.17) vs $130.9M ($2.32).
- Total net revenue Q4 $0.6M vs $11.6M, mainly from YUTIQ deferred revenue recognition.
- Cash, cash equivalents & investments $306M as of Dec 31, 2025; provides runway into Q4 2027.
- Both Phase 3 wet AMD trials (LUGANO, LUCIA) on track; topline data expected mid-2026. DME trials dosed.
- Appointed Michael Campbell as Chief Commercial Officer for DURAVYU launch readiness.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1314102/000119312526089856/0001193125-26-089856-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1314102/000119312526089856/eypt-20260304.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-089856

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer